Wednesday, August 26, 2026

Hypertension Hits Young Adults Hard — But They’re Not Getting Treated

Nearly 10 million die from hypertension yearly. Awareness is low among young adults, increasing health risks and complications.

Lotte Biologics says it has secured top-10 global CDMO manufacturing capacity [BIO USA]

Lotte Biologics is set to begin commercial production by the end of 2026, advancing its capabilities in the global CDMO market.

Frequent Delivery Meals and Abdominal Obesity Emerging as Key Drivers of Early Hypertension Risk

Increased use of delivery apps and late-night eating habits are raising hypertension and metabolic disease risks among young adults.

Tag: Belvarafenib

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Belvarafenib: The Promising New Targeted Cancer Drug for NRAS Mutant Melanoma

Hanmi Pharmaceutical presents Belvarafenib's phase 2 trial for NRAS mutant melanoma at KCA 2026, targeting unmet medical needs.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.